CTOs on the Move

Kiromic

www.kiromic.com

 
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using our proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases. Kiromic is in the process of developing a multi-indication allogeneic CAR-T cell therapy that exploits the natural potency of Gamma Delta T-cells to target solid cancers. From our heritage as a cancer vaccine development company, Kiromic is focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline. Our pipeline development is leveraged through the Company`s proprietary target discovery engine called "DIAMOND," ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kiromic.com
  • 7707 Fannin Suite 140
    Houston, TX USA 77054
  • Phone: 832.968.4888

Executives

Name Title Contact Details

Funding

Kiromic raised $40M on 06/29/2021

Similar Companies

Elite Diagnostics

Elite Diagnostics is a Anaheim, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AltMed

AltMed LLC is a fully integrated, science-based Florida company bringing compassion, community engagement and pharmaceutical industry precision to the development, production and dispensing of medical cannabis.

Patara Pharma

Patara Pharma is a biopharmaceutical company developing a new therapy for the treatment of allergic and immunologic diseases and conditions that affect orphan patient populations. We completed a Phase 1 clinical trial with favorable results and have initiated Phase 2 clinical trials for several undisclosed indications that will read-out by the end of 2015.

Affinivax

Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine. Affinivax designs each of its vaccine candidates to optimize the protective immune response to one or both of these antigens utilizing the distinctive plug-and-play nature of its proprietary MAPS™ technology platform, presenting the potential opportunity to make a significant step forward in addressing major healthcare challenges posed by novel and resistant infectious diseases. Affinivax was founded in 2014 with a seed investment from the Bill & Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Children`s Hospital.

Arzeda

Arzeda The Protein Design Company is a synthetic biology company.